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1. Introduction
Skeletal muscle tissue accounts for almost half of the human body mass. Muscle contrac-
tions of the skeletal muscle enable to move body and maintain homeostasis. Human health is 
markedly affected by any deterioration in the material, metabolic, and contractile properties 
of skeletal muscle. Skeletal muscle is a highly plastic organ that is modulated by various 
pathways controlling cell and protein turnover. Nowadays, the autophagy-dependent sys-
tem and ubiquitin-proteasome signaling are well known as a major intracellular degradation 
system, and its appropriate function is crucial to health and muscle homeostasis. Indeed, 
muscle wasting and weakness such as cachexia, atrophy, and sarcopenia are characterized 
by marked decreases in the protein content, myonuclear number, muscle fiber size, and 
muscle strength [1]. Muscle wasting elicits a poor functional status and reduces the qual-
ity of life. Thirty-five percent of all cancer patients directly die because of cachexia and not 
from cancer. Different types of molecular triggers/catabolic factors such as pro-inflammatory 
cytokines and myostatin also seem to involve muscle wasting [2]. In contrast, mTOR- or 
serum response factor (SRF)-dependent signaling are positive regulators to promote protein 
synthesis and skeletal muscle-specific mRNA transcription. Interestingly, a functional defect 
in autophagy-dependent signaling in sarcopenic mice and humans are recently suggested 
[3, 4]. Such a condition accumulates the denaturing protein and nonfunctional mitochondria 
eventually result in the atrophy of sarcopenic muscle fibers because of the deterioration of 
homeostasis.
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2. Various therapeutic approaches for muscle wasting
To attenuate various forms of muscle wasting, many researchers have investigated exercise-
based, supplemental, and pharmacological approaches. For example, the combination of 
resistance training and amino acid-containing supplements is thought to effectively prevent 
sarcopenia. In addition, myostatin inhibition for sarcopenic patients was successful in phase 
II trials, but the effect on muscular dystrophy is unclear. The administrations of ghrelin and 
megestrol acetate have shown good results against cancer cachexia [5]. Furthermore, recent 
studies [6, 7] indicated the possible application of novel supplements such as soy isoflavone 
and ursolic acid to prevent muscle atrophy in rodents. More recently, pharmacological treat-
ment with fibroblast growth factor 19 markedly ameliorated two different type of muscle 
atrophy after aging and glucocorticoid treatment, probably via an obligate co-receptor for 
fibroblast growth factor 15/19, β-Klotho.
3. The function of smooth muscle cells
Our circulatory system is modulated of the heart, lungs, and vasculature. These components 
serve crucial roles in controlling blood and lymph flow and in the delivery of gases, hormone, 
and essential nutrients (i.e., glucose, fat, or amino acids). Vascular smooth muscle cells (VSMCs) 
are the most numerous cell types in blood vessels. They are located in the medial layer of the 
vascular wall, i.e., in the tunica media. The media also contains sparse fibroblasts and macro-
phages along with an interstitial matrix consisting collagens; chondroitin sulfate proteoglycans 
including versican; glycoproteins such as tenascin, vitronectin, and fibronectin; and elastic 
laminae. VSMCs serve critical regulatory roles of blood vessels, particularly for vasoconstric-
tion, vasodilatation, and synthesis of vascular extracellular matrix. Adult blood vessels are 
normally contractile, static, and quiescent. However, under cardiovascular disease including 
atherosclerosis, hypertension, and diabetic angiopathy, VSMCs undergo phenotypic alterations 
and revert to a growth-promoting, synthetic nature. Indeed, after biochemical or mechanical 
damage to blood vessels, VSMCs undergo phenotypic modulation, characterized by increased 
proteosynthesis and by activation of the migration and growth of VSMCs [8, 9]. These changes 
often lead to severe damage to blood vessels, including stenosis and occlusion. Ischemia of the 
tissues supplied by the damaged vessels is then manifested by serious disorders, e.g., heart 
failure, brain stroke, or necrosis of leg tissues, which can result in amputation of the leg.
Vascular remodeling is an adaptive alternating process of vascular wall architecture and is 
caused by various stimuli such as vascular injury, oxidative stress, and hemodynamic stress 
[10]. VSMCs and endothelial cells compose the arteries and have essential roles in vascular 
remodeling in conjunction with inflammatory cells (macrophages, monocytes, leucocytes, 
and lymphocytes) [11]. During vascular remodeling, the infiltration of macrophages and 
monocytes, synthetic or contractile phenotypic changes of VSMCs, and the EC dysfunction 
promote vascular diseases such as atherosclerosis. Therefore, modulation of VSMC pheno-
type, maintenance of ECs, and regulation of inflammation in the vessel wall are important in 
arterial function and homeostasis.
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